news

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...

Oct 10, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...

Oct 8, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for...

Oct 2, 2024

Home

Innovating Beyond Boundaries

Powering oral therapies with proprietary technology to make a real impact.

Improving Maternal Mental Health

LPCN 1154 (BRLIZIO) is under development for postpartum depression (PPD) treatment targeting Rapid Relief with a 48-hour oral treatment.

Transforming Depression Treatment

Reimagining depression care with a convenient fast-acting, non-dissociative oral antidepressant.

Pipeline & Product

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 Mar 10, 2026

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) Feb 18, 2026

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Jan 20, 2026

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Jan 12, 2026

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone Dec 16, 2025

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Nov 18, 2025

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 Nov 6, 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® Nov 4, 2025

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) Sep 30, 2025

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference Sep 5, 2025

Therapeutic TargetsBest-in-Class therapy option for clinically significant conditions

Postpartum Depression

Major Depressive Disorder

Epilepsy

Essential Tremor

Cirrhosis

Obesity Management

Preterm Birth

Hypogonadism

Pipeline & Product

Built on its drug delivery technology platform, Lipcoine’s pipeline of products target serious conditions with significant unmet medical needs in large addressable markets.

Pipeline Candidates

LPCN 1154

Treatment of Postpartum Depression

LPCN 2201

Treatment for Major Depressive Disorder

LPCN 2101

Drug Resistant Epilepsy

LPCN 2203

Treatment of Essential Tremor

LPCN 1148

Treatment of Liver Cirrhosis

LPCN 2401

Obesity Management – adjunct to GLP-1

LPCN 1107

Prevention of Recurrent Pre-Term Birth

Product

Testosterone replacement therapy

TLANDO offers the simplicity and convenience of oral dosing for TRT.

Visit TLANDO website

Innovating beyond
boundaries for patients